Impacts of activation of the mitogen-activated protein kinase pathway in pancreatic cancer

Frontiers in Oncology

Volumn 5, Issue FEB, 2015, Pages

  Furukawa, Toru ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

BRAF; DUSP6; ERK; KRAS; microRNA; Mitogen activated protein kinase; MKP 3; Pancreatic cancer

Indexed keywords

AURORA A KINASE; AZACITIDINE; DUAL SPECIFICITY PHOSPHATASE 6; MICRORNA; MICRORNA 34A; MITOGEN ACTIVATED PROTEIN KINASE; TUMOR PROTEIN;

ENZYME ACTIVATION; FEEDBACK SYSTEM; GENE; GENE DOSAGE; GENE EXPRESSION; GENE MUTATION; HUMAN; ONCOGENE K RAS; PANCREAS ADENOMA; PANCREAS CANCER; REVIEW; SIGNAL TRANSDUCTION; SON GENE;

EID: 84923581093     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2015.00023     Document Type: Review

References (47)

1. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H. Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol (2014) 44(4):388-96. doi:10.1093/jjco/hyu003.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin (2009) 59(4):225-49. doi:10.3322/caac.20006.
3. Berrino F, De Angelis R, Sant M, Rosso S, Bielska-Lasota M, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. Lancet Oncol (2007) 8(9):773-83. doi:10.1016/S1470-2045(07)70245-0.
4. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell (1988) 53(4):549-54. doi:10.1016/0092-8674(88)90571-5.
5. Thatcher JD. The Ras-MAPK signal transduction pathway. Sci Signal (2010) 3(119):tr1. doi:10.1126/scisignal.3119tr1.
6. Gibbs JB, Sigal IS, Poe M, Scolnick EM. Intrinsic GTPase activity distinguishes normal and oncogenic ras p21 molecules. Proc Natl Acad Sci U S A (1984) 81(18):5704-8. doi:10.1073/pnas.81.18.5704.
7. Calhoun ES, Jones JB, Ashfaq R, Adsay V, Baker SJ, Valentine V, et al. BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. Am J Pathol (2003) 163(4):1255-60. doi:10.1016/S0002-9440(10)63485-2.
8. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417(6892):949-54. doi:10.1038/nature00766.
9. Johnson GL, Lapadat R. Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 298(5600):1911-2. doi:10.1126/science.1072682.
10. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J (1999) 18(3):664-74. doi:10.1093/emboj/18.3.664.
11. Stewart AE, Dowd S, Keyse SM, McDonald NQ. Crystal structure of the MAPK phosphatase Pyst1 catalytic domain and implications for regulated activation. Nat Struct Biol (1999) 6(2):174-81. doi:10.1038/5861.
12. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer Metastasis Rev (2008) 27(2):253-61. doi:10.1007/s10555-008-9123-1.
13. Farooq A, Chaturvedi G, Mujtaba S, Plotnikova O, Zeng L, Dhalluin C, et al. Solution structure of ERK2 binding domain of MAPK phosphatase MKP-3: structural insights into MKP-3 activation by ERK2. Mol Cell (2001) 7(2):387-99. doi:10.1016/S1097-2765(01)00186-1.
14. Kimura M, Furukawa T, Abe T, Yatsuoka T, Youssef EM, Yokoyama T, et al. Identification of two common regions of allelic loss in chromosome arm 12q in human pancreatic cancer. Cancer Res (1998) 58(11):2456-60.
15. Furukawa T, Yatsuoka T, Youssef EM, Abe T, Yokoyama T, Fukushige S, et al. Genomic analysis of DUSP6, a dual specificity MAP kinase phosphatase, in pancreatic cancer. Cytogenet Cell Genet (1998) 82(3-4):156-9. doi:10.1159/000015091.
16. Furukawa T, Sunamura M, Motoi F, Matsuno S, Horii A. Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer. Am J Pathol (2003) 162(6):1807-15. doi:10.1016/S0002-9440(10)64315-5.
17. Xu S, Furukawa T, Kanai N, Sunamura M, Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet (2005) 50(4):159-67. doi:10.1007/s10038-005-0235-y.
18. Furukawa T, Tanji E, Xu S, Horii A. Feedback regulation of DUSP6 transcription responding to MAPK1 via ETS2 in human cells. Biochem Biophys Res Commun (2008) 377(1):317-20. doi:10.1016/j.bbrc.2008.10.003.
19. Hruban RH, Goggins M, Parsons J, Kern SE. Progression model for pancreatic cancer. Clin Cancer Res (2000) 6(8):2969-72.
20. Hruban RH, Adsay NV, Albores-Saavedra J, Compton C, Garrett ES, Goodman SN, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol (2001) 25(5):579-86. doi:10.1097/00000478-200105000-00003.
21. Furukawa T, Fujisaki R, Yoshida Y, Kanai N, Sunamura M, Abe T, et al. Distinct progression pathways involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms of the pancreas. Mod Pathol (2005) 18(8):1034-42. doi:10.1038/modpathol.3800383.
22. Marchetti S, Gimond C, Chambard JC, Touboul T, Roux D, Pouyssegur J, et al. Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation. Mol Cell Biol (2005) 25(2):854-64. doi:10.1128/MCB.25.2.854-864.2005.
23. Chan DW, Liu VW, Tsao GS, Yao KM, Furukawa T, Chan KK, et al. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis (2008) 29(9):1742-50. doi:10.1093/carcin/bgn167.
24. Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A. AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene (2006) 25(35):4831-9. doi:10.1038/sj.onc.1209494.
25. Zhou H, Kuang J, Zhong L, Kuo WL, Gray JW, Sahin A, et al. Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat Genet (1998) 20(2):189-93. doi:10.1038/2496.
26. Foulds CE, Nelson ML, Blaszczak AG, Graves BJ. Ras/mitogen-activated protein kinase signaling activates Ets-1 and Ets-2 by CBP/p300 recruitment. Mol Cell Biol (2004) 24(24):10954-64. doi:10.1128/MCB.24.24.10954-10964.2004.
27. Hata T, Furukawa T, Sunamura M, Egawa S, Motoi F, Ohmura N, et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res (2005) 65(7):2899-905. doi:10.1158/0008-5472.CAN-04-3981.
28. Furukawa T, Tanji E, Kuboki Y, Hatori T, Yamamoto M, Shimizu K, et al. Targeting of MAPK-associated molecules identifies SON as a prime target to attenuate the proliferation and tumorigenicity of pancreatic cancer cells. Mol Cancer (2012) 11:88. doi:10.1186/1476-4598-11-88.
29. Ahn EY, DeKelver RC, Lo MC, Nguyen TA, Matsuura S, Boyapati A, et al. SON controls cell-cycle progression by coordinated regulation of RNA splicing. Mol Cell (2011) 42(2):185-98. doi:10.1016/j.molcel.2011.03.014.
30. Sharma A, Takata H, Shibahara K, Bubulya A, Bubulya PA. Son is essential for nuclear speckle organization and cell cycle progression. Mol Biol Cell (2010) 21(4):650-63. doi:10.1091/mbc.E09-02-0126.
31. Teoh PL, Sharrocks AD. WDR5, ASH2L, and RBBP5 control the efficiency of FOS transcript processing. Cell Mol Biol Lett (2014) 19(2):215-32. doi:10.2478/s11658-014-0190-8.
32. Boeckx C, Op de Beeck K, Wouters A, Deschoolmeester V, Limame R, Zwaenepoel K, et al. Overcoming cetuximab resistance in HNSCC: the role of AURKB and DUSP proteins. Cancer Lett (2014) 354(2):365-77. doi:10.1016/j.canlet.2014.08.039.
33. Zhang C, Han Y, Huang H, Min L, Qu L, Shou C. Integrated analysis of expression profiling data identifies three genes in correlation with poor prognosis of triple-negative breast cancer. Int J Oncol (2014) 44(6):2025-33. doi:10.3892/ijo.2014.2352.
34. Liao P, Wang W, Shen M, Pan W, Zhang K, Wang R, et al. A positive feedback loop between EBP2 and c-Myc regulates rDNA transcription, cell proliferation, and tumorigenesis. Cell Death Dis (2014) 5:e1032. doi:10.1038/cddis.2013.536.
35. Wang F, Lin SL. Knockdown of kinesin KIF11 abrogates directed migration in response to epidermal growth factor-mediated chemotaxis. Biochem Biophys Res Commun (2014) 452(3):642-8. doi:10.1016/j.bbrc.2014.08.136.
36. Huerta M, Fernandez-Marquez J, Cabello JL, Medrano A, Querol E, Cedano J. Analysis of gene expression for studying tumor progression: the case of glucocorticoid administration. Gene (2014) 549(1):33-40. doi:10.1016/j.gene.2014.07.027.
37. Liu HC, Zhang GH, Liu YH, Wang P, Ma JF, Su LS, et al. TPX2 siRNA regulates growth and invasion of esophageal cancer cells. Biomed Pharmacother (2014) 68(7):833-9. doi:10.1016/j.biopha.2014.08.008.
38. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science (2001) 294(5543):853-8. doi:10.1126/science.1064921.
39. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature (2010) 466(7308):835-40. doi:10.1038/nature09267.
40. Visone R, Croce CM. MiRNAs and cancer. Am J Pathol (2009) 174(4):1131-8. doi:10.2353/ajpath.2009.080794.
41. Ikeda Y, Tanji E, Makino N, Kawata S, Furukawa T. MicroRNAs associated with mitogen-activated protein kinase in human pancreatic cancer. Mol Cancer Res (2012) 10(2):259-69. doi:10.1158/1541-7786.MCR-11-0035.
42. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature (2007) 447(7148):1130-4. doi:10.1038/nature05939.
43. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 26(5):745-52. doi:10.1016/j.molcel.2007.05.010.
44. Tiedje C, Holtmann H, Gaestel M. The role of mammalian MAPK signaling in regulation of cytokine mRNA stability and translation. J Interferon Cytokine Res (2014) 34(4):220-32. doi:10.1089/jir.2013.0146.
45. Li J, Kong F, Wu K, Song K, He J, Sun W. miR-193b directly targets STMN1 and uPA genes and suppresses tumor growth and metastasis in pancreatic cancer. Mol Med Rep (2014) 10(5):2613-20. doi:10.3892/mmr.2014.2558.
46. Liu SM, Lu J, Lee HC, Chung FH, Ma N. miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2. Oncotarget (2014) 5(19):9444-59.
47. Giltnane JM, Balko JM. Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. Discov Med (2014) 17(95):275-83.